/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease.
$34.56
$0.37 (-1.06%)
EOD Sep 1, 2026
Margins and capital returns are both well above average: 21.15% operating margin, ROIC at 64.19%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 4.3%, steady but not accelerating. Free cash flow declined 1429% despite revenue growth, conversion is weakening.
Free cash flow declined 1429% versus the prior year, cash generation momentum has weakened. Negative free cash flow of -$93M. The business is consuming cash, not generating it.
12.4x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.33B
▲ +4.3% YoY
Net Income (TTM)
$356M
▲ +2900.0% YoY
Op. Margin
31.63%
▲ +17.9pp YoY
ROIC
88.81%
▲ +56.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$111M
▼ -1428.6% YoY
Op. Cash Flow (TTM)
-$40M
▼ -175.0% YoY
Net Debt
$287M
Cash & Equiv.
$222M
3Y CAGR: +11.2%
Continue Research
SourceComputed from the 10-Q filed 3 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 4 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 12.4, Indivior Pharmaceuticals (INDV)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Indivior Pharmaceuticals scores 59/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Indivior Pharmaceuticals scores 59 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 31.6% operating margin and a 88.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh INDV's valuation and scores 59/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.